Coverage
-
January 28, 2016
A Nevada federal judge has given preliminary approval of a $7 million settlement between Spectrum Pharmaceuticals Inc. and a class of shareholders accusing the company of not properly disclosing that a generic of its cancer drug Fusilev was about to dramatically decrease demand for the brand-name drug.
2 other articles on this case.
View all »